Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy

IMPORTANCE: Approximately 45% to 60% of hormone receptor (HR)–positive metastatic breast cancer (mBC) shows a low-level expression of ERBB2. Low ERBB2 expression is defined as ERBB2 immunohistochemical expression of 1+ or 2+ with a negative ERBB2 amplification by in situ hybridization. The efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouabbi, Jason A., Singareeka Raghavendra, Akshara, Bassett, Roland L., Hassan, Amy, Tripathy, Debasish, Layman, Rachel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176119/
https://www.ncbi.nlm.nih.gov/pubmed/37166793
http://dx.doi.org/10.1001/jamanetworkopen.2023.13017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176119/
https://www.ncbi.nlm.nih.gov/pubmed/37166793
http://dx.doi.org/10.1001/jamanetworkopen.2023.13017

Ejemplares similares